Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dold

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
The American Journal of Psychiatry|September 1, 2022
Psychotherapy's Role for Treatment-Resistant Depression?Lucie Bartova, Gernot Fugger, Markus Dold, et al.
The Cochrane Database of Systematic Reviews|November 16, 2012
Benzodiazepines for schizophreniaMarkus Dold, Chunbo Li, Magdolna Tardy, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 3, 2023
Silexan for treatment of anxiety and depression in the context of COVID-19Lucie Bartova, Markus Dold, Gernot Fugger, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|February 27, 2016
Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trialsMarkus Dold, Magdolna Tardy, Myrto T Samara, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 9, 2022
Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisitedLucie Bartova, Markus Dold, Hans-Peter Volz, et al.
JAMA Psychiatry|February 5, 2016
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysisMyrto T Samara, Markus Dold, Myrsini Gianatsi, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 30, 2023
Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trialsMarkus Dold, Lucie Bartova, Hans-Peter Volz, et al.
Journal of Affective Disorders|December 20, 2017
Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depressionPaolo Olgiati, Alessandro Serretti, Daniel Souery, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 26, 2018
Rapid antidepressant effect of S-ketamine in schizophreniaLucie Bartova, Konstantinos Papageorgiou, Ivan Milenkovic, et al.
The Journal of ECT|May 19, 2017
Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case ReportLucie Bartova, Ana Weidenauer, Markus Dold, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
The American Journal of Psychiatry|September 1, 2022
Psychotherapy's Role for Treatment-Resistant Depression?Lucie Bartova, Gernot Fugger, Markus Dold, et al.
The Cochrane Database of Systematic Reviews|November 16, 2012
Benzodiazepines for schizophreniaMarkus Dold, Chunbo Li, Magdolna Tardy, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 3, 2023
Silexan for treatment of anxiety and depression in the context of COVID-19Lucie Bartova, Markus Dold, Gernot Fugger, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|February 27, 2016
Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trialsMarkus Dold, Magdolna Tardy, Myrto T Samara, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 9, 2022
Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisitedLucie Bartova, Markus Dold, Hans-Peter Volz, et al.
JAMA Psychiatry|February 5, 2016
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysisMyrto T Samara, Markus Dold, Myrsini Gianatsi, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 30, 2023
Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trialsMarkus Dold, Lucie Bartova, Hans-Peter Volz, et al.
Journal of Affective Disorders|December 20, 2017
Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depressionPaolo Olgiati, Alessandro Serretti, Daniel Souery, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 26, 2018
Rapid antidepressant effect of S-ketamine in schizophreniaLucie Bartova, Konstantinos Papageorgiou, Ivan Milenkovic, et al.
The Journal of ECT|May 19, 2017
Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case ReportLucie Bartova, Ana Weidenauer, Markus Dold, et al.
Pageof 7